Stockscreener 앱 받기
4.38
1.86%
0.08
시간 외 거래:
4.38
전일 마감가:
$4.30
열려 있는:
$4.44
하루 거래량:
6,507
Relative Volume:
0.56
시가총액:
$13.80M
수익:
$37.20M
순이익/손실:
$-11.85M
주가수익비율:
-22.96
EPS:
-0.1908
순현금흐름:
$-10.59M
1주 성능:
-23.83%
1개월 성능:
-38.36%
6개월 성능:
-67.38%
1년 성능:
-76.35%
1일 변동 폭
$4.33
$4.8275
1주일 범위
$3.94
$5.79
52주 변동 폭
$3.94
$20.40
Cytosorbents Corp Stock (CTSO) Company Profile
명칭
Cytosorbents Corp
전화
973-329-8885
주소
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
4.38 | 13.80M | 37.20M | -11.85M | -10.59M | -0.1908 |
ABT
Abbott Laboratories
|
101.29 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
88.64 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.36 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.92 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.29 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-07 | 개시 | B. Riley Securities | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2020-09-17 | 개시 | Jefferies | Buy |
| 2020-09-01 | 개시 | SVB Leerink | Outperform |
| 2017-08-08 | 재확인 | Maxim Group | Buy |
| 2016-10-26 | 개시 | Aegis Capital | Buy |
| 2016-05-24 | 개시 | Maxim Group | Buy |
| 2015-10-29 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | 재확인 | MLV & Co | Buy |
| 2015-04-01 | 재확인 | MLV & Co | Buy |
| 2015-03-05 | 개시 | MLV & Co | Buy |
| 2015-02-25 | 개시 | WBB Securities | Speculative Buy |
| 2015-01-27 | 재확인 | H.C. Wainwright | Buy |
모두보기
Cytosorbents Corp 주식(CTSO)의 최신 뉴스
Cytosorbents Corporation (CTSO) stock price, news, quote and history - Yahoo Finance UK
CytoSorbents regains Nasdaq $1.00 minimum bid compliance; MVLS shortfall remains under review - TradingView
Nasdaq keeps CytoSorbents (NASDAQ: CTSO) on watch after $1 bid price return - Stock Titan
CytoSorbents regains Nasdaq minimum bid price compliance - Investing.com
Cytosorbents Corporation (CTSO) Stock Price, News, Quote & History - Yahoo! Finance Canada
CytoSorbents Regains Compliance With Nasdaq Minimum Bid Price Requirement - Moomoo
Cytosorbents Corp (CTSO) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (CTSO) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (CTSO) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (HQE) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Cytosorbents Corp (HQE) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
CEO Phillip Chan Buys 3,774 Shares of CytoSorbents Corp (CTSO) - GuruFocus
Cytosorbents president & COO Vincent Capponi buys $12,536 in stock By Investing.com - Investing.com Australia
Cytosorbents CEO Phillip Chan buys $22,644 in common stock - Investing.com
Cytosorbents (CTSO) CEO adds to stake in open-market buy - Stock Titan
Cytosorbents president & COO Vincent Capponi buys $12,536 in stock - Investing.com
Cytosorbents (CTSO) director buys shares in open-market trades without a preset plan - Stock Titan
Cytosorbents (CTSO) COO adds shares in open‑market buy - Stock Titan
CytoSorbents at H.C. Wainwright conference: breakeven, drug hopes - Investing.com
CytoSorbents Corp (STU:HQE) Stock Price & 30 Year Financial Data - GuruFocus
CytoSorbents to present at H.C. Wainwright conf... - Pluang
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 By Investing.com - Investing.com South Africa
Cytosorbents CEO Phillip Chan buys 200,000 shares for $70,000 - Investing.com
Cytosorbents Corp (CTSO) CEO bought more shares in the open market, adding to his stake - Stock Titan
CytoSorbents Corp (STU:HQE) Stock Earnings Transcripts - GuruFocus
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights - easternprogress.com
CytoSorbents to present at Moody Capital Soluti... - Pluang
CytoSorbents to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - The Globe and Mail
CytoSorbents Plans 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing - citybiz
CytoSorbents to implement 1-for-20 reverse stoc... - Pluang
CytoSorbents Announces Reverse Stock Split - Morningstar
CTSO Looks 61.4% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus
CytoSorb reduces severe bleeding by 37% in urge... - pluang.com
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings - Yahoo Finance
Cytosorbents Earnings Call Balances Progress and Risk - The Globe and Mail
Cytosorbents (CTSO) Chart: Finishes 20.35% Higher at $0.37 for the Current Session; Market Levels: Traders Can Monitor the $0.35-$0.39 Range in the Current UpdateMerger Arbitrage - dars.gov.et
Cytosorbents (CTSO) Shares: Finishes 5.62% Higher at $0.38; Levels: Support at $0.36 and Resistance at $0.40 Frame the Range on the DayDividend Stock Picks - careplusvn.com
Cytosorbents (CTSO) Financial Update: EPS Comes in Below Forecast; Market Follow-Through: Shares Finish 4.56% LowerEarnings Season Outlook - vinanet.vn
CTSO: CytoSorbents Future Value Drivers Support Price Target of $4.00 - Yahoo Finance
CytoSorbents (CTSO) wins approval for reverse split and director slate at 2026 meeting - Stock Titan
Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Cytosorbents Corp. R (HQE1.DU) Q1 FY2026 earnings call transcript - Yahoo Finance
Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q2 2026 Cytosorbents Corp Earnings Call Transcript - GuruFocus
Cytosorbents Corp (CTSO) Stock News Today - TradingKey
CytoSorbents posts $9.6M Q2 revenue, narrows cash burn and advances DrugSorb-ATR regulatory path - TradingView
Cytosorbents Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nea - GuruFocus
Is CytoSorbents Corp (CTSO) a Value Opportunity After Q2 Earning - GuruFocus
CytoSorbents Corp (CTSO) (Q2 2026) Earnings Call Highlights: Nearing Breakeven with Strong ... - finance.yahoo.com
Cytosorbents Corp (CTSO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.51%
0.97%
자본화:
|
볼륨(24시간):